Evidence map›Paper›PMID 42440437›Full record

ArticleFrontiers in oncology2026

Association between radiotherapy timing and intracranial outcomes in EGFR-mutant NSCLC with brain metastases treated with EGFR-TKIs.

Qi Liu, Jian Shi, Ruiyu Liu, Zhuofan Wang, Rong Qiu, Yunfan Wu, Juan Li, Yuxiang Wang

Abstract read
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Qi LiuDepartment of Radiation Oncology, the Fourth Hospital of Hebei Medical University & Hebei Clinical Research Center for Radiation Oncology, Shijiazhuang, China.
Jian ShiDepartment of Oncology, the Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Ruiyu LiuDepartment of Radiation Oncology, the Fourth Hospital of Hebei Medical University & Hebei Clinical Research Center for Radiation Oncology, Shijiazhuang, China.
Zhuofan WangDepartment of Radiation Oncology, the Fourth Hospital of Hebei Medical University & Hebei Clinical Research Center for Radiation Oncology, Shijiazhuang, China.
Rong QiuDepartment of Radiation Oncology, the Fourth Hospital of Hebei Medical University & Hebei Clinical Research Center for Radiation Oncology, Shijiazhuang, China.
Yunfan WuDepartment of Radiation Oncology, the Fourth Hospital of Hebei Medical University & Hebei Clinical Research Center for Radiation Oncology, Shijiazhuang, China.
Juan LiDepartment of Radiation Oncology, the Fourth Hospital of Hebei Medical University & Hebei Clinical Research Center for Radiation Oncology, Shijiazhuang, China.
Yuxiang WangDepartment of Radiation Oncology, the Fourth Hospital of Hebei Medical University & Hebei Clinical Research Center for Radiation Oncology, Shijiazhuang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study evaluated the treatment outcomes and prognostic factors that influence the overall survival (OS) and intracranial progression-free survival (iPFS) in patients with epidermal growth factor receptor ( Methods: The clinical data obtained from patients diagnosed with Results: A total of 135 patients were included. Among them, 70 patients (51.9%) received early RT, while 65 patients (48.1%) received delayed RT. All patients were treated with EGFR-TKIs, either before or during RT. In the univariate analysis, the Conclusion: The combination of EGFR-TKIs with early RT can enhance the intracranial disease control in patients with

Indexed as

brain metastasesdelayed RTearly RTepidermal growth factor receptornon-small cell lung cancer

Identifiers

PMID42440437
PMCPMC13333384

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.